Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Slides:

Advertisements

Similar presentations

Assessment of inflammation in noninfectious chronic maxillary sinusitis Pascal Demoly, MDa, Louis Crampette, MDb, Michel Mondain, MDb, Alison M. Campbell,

Advertisements

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Evaluation and treatment of allergic fungal sinusitis. II

Relationship of nasal carriage of Staphylococcus aureus to pathogenesis of perennial allergic rhinitis Teruo Shiomori, MDa, Shin-ichi Yoshida, MD, PhDb,

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Ulrich Wahn, MDa. ‡, Eli O. Meltzer, MDb. ‡, Albert F. Finn, MDc

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis William R. Lumry, MD Journal of.

Eosinophil cationic protein and histamine after intestinal challenge in patients with cow's milk intolerance Ulf Bengtsson, MD, PhDa, Tina W. Knutson,

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children Mark Boguniewicz, MDa, Virginia C. Fiedler,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Evaluation and treatment of allergic fungal sinusitis. II

The effect of omalizumab on nasal allergic inflammation

Subjects with seasonal allergic rhinitis and nonrhinitic subjects react differentially to nasal provocation with chlorine gas Dennis J. Shusterman, MD,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Badrul A. Chowdhury, MD, PhD

Inflammation of small airways in asthma

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Product characteristics and pharmacokinetics of intranasal ipratropium bromide Chester C. Wood, MDa, Philip Fireman, MDb, Jay Grossman, MDc, Margaret.

Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure Margherita Tomassini, MDa, Laura Magrini, MDa, Guido De.

Anaphylactic reaction to local administration of rifamycin SV

Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic.

Increased sensitivity to bradykinin among African Americans

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model John M.

A review of the current guidelines for allergic rhinitis and asthma

Physician-targeted program on inhaled therapy for childhood asthma

Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: Effects of single allergen challenge Adriaan.

Quality of life in adults and children with allergic rhinitis

James P. Kemp, MDa, David A. Cook, MDb, Gary A

The Editors' Choice Journal of Allergy and Clinical Immunology

Molecular virology and immunology of HIV infection

Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids Keisuke.

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis Robert P. Harvey, MD, Carolyn Comer, MD, Barbara Sanders, MD, Ross Westley,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Thomas B. Casale, MDa, I. Leonard Bernstein, MDb, William W

Quantitation of H1-receptor antagonists in skin and serum

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic.

Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation Alex.

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma Yasurou Kohno, MDa,

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

Assessment of inflammation in noninfectious chronic maxillary sinusitis Pascal Demoly, MDa, Louis Crampette, MDb, Michel Mondain, MDb, Alison M. Campbell,

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

Loratadine reduces allergen-induced mucosal output of α2-macroglobulin and tryptase in allergic rhinitis Lennart Greiff, MD, PhDa, Carl G.A. Persson,

Chemokines in seasonal allergic rhinitis

Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis Toyoyuki Hanazawa, MD, PhD, Julio.

Corticosteroids in the treatment of pediatric allergic rhinitis

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma Sally E. Wenzel, MD Journal of Allergy and Clinical.

Jonathan M. Corne, MRCPa, Catherine H. Linaker, BNa, Peter H

Larry C. Borish, MDa, Harold S

Relationship of nasal carriage of Staphylococcus aureus to pathogenesis of perennial allergic rhinitis Teruo Shiomori, MDa, Shin-ichi Yoshida, MD, PhDb,

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis Warner Carr, MD, Jonathan Bernstein, MD, Phil Lieberman,

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa,

Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal.

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Desloratadine: A new, nonsedating, oral antihistamine

Presentation transcript:

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer, MDa, b, Alfredo A. Jalowayski, PhDb, H.Alice Orgel, MD, PhDa, b, Alan G. Harris, MDc Journal of Allergy and Clinical Immunology Volume 102, Issue 1, Pages 39-49 (July 1998) DOI: 10.1016/S0091-6749(98)70053-3 Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 1 Total SAR symptom/sign score (mean ± SEM). Sum of separate nasal and nonnasal scores, with clinician and patient assessments for morning and evening. *p < 0.05, mometasone furoate versus placebo. Journal of Allergy and Clinical Immunology 1998 102, 39-49DOI: (10.1016/S0091-6749(98)70053-3) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 2 Nasal symptom/sign score (mean) for each symptom on each visit, with clinician and patient evening assessments. *p < 0.05; **p < 0.01, mometasone furoate versus placebo. B, Baseline. Journal of Allergy and Clinical Immunology 1998 102, 39-49DOI: (10.1016/S0091-6749(98)70053-3) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 3 Clinician and patient assessment of therapeutic response. Percent of patients in mometasone furoate and placebo treatment groups with each rating of improvement on day 8 and day 15. *p < 0.05 mometasone furoate versus placebo. Journal of Allergy and Clinical Immunology 1998 102, 39-49DOI: (10.1016/S0091-6749(98)70053-3) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 4 Percent of patients with increase or decrease in eosinophils, basophils, and neutrophils among those with evaluable paired pre- and posttreatment specimens. *p ≤ 0.05; **p ≤ 0.001, mometasone furoate versus placebo. p ≤ 0.05 baseline to day 15 within treatment. Journal of Allergy and Clinical Immunology 1998 102, 39-49DOI: (10.1016/S0091-6749(98)70053-3) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 5 Concentration (mean ± SEM) of ECP, tryptase, histamine, and albumin in NL fluid at baseline and day 15. *p ≤ 0.05, **p ≤ 0.001 within treatment, baseline to day 15. Journal of Allergy and Clinical Immunology 1998 102, 39-49DOI: (10.1016/S0091-6749(98)70053-3) Copyright © 1998 Mosby, Inc. Terms and Conditions